Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Halozyme Appoints Michael LaBarre CSO

This article was originally published in Scrip

Executive Summary

Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, has promoted Dr. Michael J. LaBarre to chief scientific officer, succeeding Dr. Michael Shepard, who has been appointed a research fellow for the company. The move broadens LaBarre's responsibilities to include R&D of early pipeline assets, in addition to his role managing product development and Halozyme's Enhanze platform partnerships. Prior to joining Halozyme in 2008, he was vice-president, product development at Paramount BioSciences LLC; director, analytical and protein biochemistry, discovery research at Biogen Idec; and director analytical and formulation sciences, research and development at Idec Pharmaceuticals.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029638

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel